Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 263

1.

Case-based review: ependymomas in adults.

Cachia D, Johnson DR, Kaufmann TJ, Lowe S, Andersen S, Olar A, Cooper SL, Frankel BM, Gilbert MR.

Neurooncol Pract. 2018 Aug;5(3):142-153. doi: 10.1093/nop/npy026. Epub 2018 Jul 24. Review.

2.

Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials.

Molinari E, Mendoza TR, Gilbert MR.

Neurooncol Pract. 2019 Mar;6(2):81-92. doi: 10.1093/nop/npy032. Epub 2018 Aug 7. Review.

PMID:
31386029
3.

Toward Single-Organelle Lipidomics in Live Cells.

Lita A, Kuzmin AN, Pliss A, Baev A, Rzhevskii A, Gilbert MR, Larion M, Prasad PN.

Anal Chem. 2019 Aug 19. doi: 10.1021/acs.analchem.9b02663. [Epub ahead of print]

PMID:
31381322
4.

Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.

Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun M, Cao X, Wang Y, Guo L, Indig I, Rosenblum J, Ji C, Cao D, Yang K, Gilbert MR, Yao Y, Zhuang Z.

Neuro Oncol. 2019 Jul 4. pii: noz117. doi: 10.1093/neuonc/noz117. [Epub ahead of print]

PMID:
31276594
5.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
6.

Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS.

J Neurooncol. 2019 Aug;144(1):53-63. doi: 10.1007/s11060-019-03215-x. Epub 2019 Jun 17.

PMID:
31209773
7.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
8.

A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function Mutation.

Wang H, Cui J, Yang C, Rosenblum JS, Zhang Q, Song Q, Pang Y, Fang F, Sun M, Dmitriev P, Gilbert MR, Eisenhofer G, Pacak K, Zhuang Z.

Cancers (Basel). 2019 May 14;11(5). pii: E667. doi: 10.3390/cancers11050667.

9.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

10.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

11.

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.

Larion M, Dowdy T, Ruiz-Rodado V, Meyer MW, Song H, Zhang W, Davis D, Gilbert MR, Lita A.

Biosensors (Basel). 2018 Dec 28;9(1). pii: E5. doi: 10.3390/bios9010005.

12.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE.

Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17.

PMID:
30559168
13.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
14.

Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.

Radiology. 2019 Feb;290(2):467-476. doi: 10.1148/radiol.2019181296. Epub 2018 Nov 27.

PMID:
30480488
15.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
16.

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085.

17.

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.

Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK.

Neurosurgery. 2019 Apr 1;84(4):945-953. doi: 10.1093/neuros/nyy392.

PMID:
30189044
18.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

19.

Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.

Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Giles AJ, Gilbert MR, Quezado M, Nduom EK.

Neurosurgery. 2019 Aug 1;85(2):280-289. doi: 10.1093/neuros/nyy268.

PMID:
30011045
20.

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.

J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5.

Supplemental Content

Loading ...
Support Center